J. Zhang

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations.

H. Scher, A. Bryce, W. Abida, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.